High-power thulium laser vaporization of the prostate: short-term outcomes of safety and effectiveness.
Identifieur interne : 000165 ( PubMed/Corpus ); précédent : 000164; suivant : 000166High-power thulium laser vaporization of the prostate: short-term outcomes of safety and effectiveness.
Auteurs : Joseph J. Pariser ; Olufenwa J. Famakinwa ; Shane M. Pearce ; Doreen E. ChungSource :
- Journal of endourology / Endourological Society [ 1557-900X ] ; 2014.
English descriptors
- KwdEn :
- Aged, Biomarkers (analysis), Cohort Studies, Humans, Laser Therapy (adverse effects), Laser Therapy (methods), Lasers, Solid-State (therapeutic use), Male, Middle Aged, Postoperative Complications, Prostate-Specific Antigen (analysis), Prostatic Hyperplasia (physiopathology), Prostatic Hyperplasia (surgery), Quality of Life, Safety, Thulium (therapeutic use), Transurethral Resection of Prostate (adverse effects), Transurethral Resection of Prostate (methods), Urinary Tract Infections (etiology), Urination (physiology), Volatilization.
- MESH :
- chemical , analysis : Biomarkers, Prostate-Specific Antigen.
- adverse effects : Laser Therapy, Transurethral Resection of Prostate.
- etiology : Urinary Tract Infections.
- methods : Laser Therapy, Transurethral Resection of Prostate.
- physiology : Urination.
- physiopathology : Prostatic Hyperplasia.
- surgery : Prostatic Hyperplasia.
- therapeutic use : Lasers, Solid-State, Thulium.
- Aged, Cohort Studies, Humans, Male, Middle Aged, Postoperative Complications, Quality of Life, Safety, Volatilization.
Abstract
The thulium laser was introduced in 2005 for the treatment of benign prostatic hyperplasia (BPH). Enucleation studies from outside North America show comparable efficacy and lower morbidity to transurethral resection of the prostate. A few studies exist describing outcomes of vaporization, the most commonly used technique for urologists. We present our 3-month outcomes of thulium laser vaporization of the prostate (ThuVP).
DOI: 10.1089/end.2014.0336
PubMed: 24936718
Links to Exploration step
pubmed:24936718Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">High-power thulium laser vaporization of the prostate: short-term outcomes of safety and effectiveness.</title><author><name sortKey="Pariser, Joseph J" sort="Pariser, Joseph J" uniqKey="Pariser J" first="Joseph J" last="Pariser">Joseph J. Pariser</name><affiliation><nlm:affiliation>1 Section of Urology, University of Chicago , Chicago, Illinois.</nlm:affiliation></affiliation></author><author><name sortKey="Famakinwa, Olufenwa J" sort="Famakinwa, Olufenwa J" uniqKey="Famakinwa O" first="Olufenwa J" last="Famakinwa">Olufenwa J. Famakinwa</name></author><author><name sortKey="Pearce, Shane M" sort="Pearce, Shane M" uniqKey="Pearce S" first="Shane M" last="Pearce">Shane M. Pearce</name></author><author><name sortKey="Chung, Doreen E" sort="Chung, Doreen E" uniqKey="Chung D" first="Doreen E" last="Chung">Doreen E. Chung</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2014">2014</date><idno type="doi">10.1089/end.2014.0336</idno><idno type="RBID">pubmed:24936718</idno><idno type="pmid">24936718</idno><idno type="wicri:Area/PubMed/Corpus">000165</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000165</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">High-power thulium laser vaporization of the prostate: short-term outcomes of safety and effectiveness.</title><author><name sortKey="Pariser, Joseph J" sort="Pariser, Joseph J" uniqKey="Pariser J" first="Joseph J" last="Pariser">Joseph J. Pariser</name><affiliation><nlm:affiliation>1 Section of Urology, University of Chicago , Chicago, Illinois.</nlm:affiliation></affiliation></author><author><name sortKey="Famakinwa, Olufenwa J" sort="Famakinwa, Olufenwa J" uniqKey="Famakinwa O" first="Olufenwa J" last="Famakinwa">Olufenwa J. Famakinwa</name></author><author><name sortKey="Pearce, Shane M" sort="Pearce, Shane M" uniqKey="Pearce S" first="Shane M" last="Pearce">Shane M. Pearce</name></author><author><name sortKey="Chung, Doreen E" sort="Chung, Doreen E" uniqKey="Chung D" first="Doreen E" last="Chung">Doreen E. Chung</name></author></analytic><series><title level="j">Journal of endourology / Endourological Society</title><idno type="eISSN">1557-900X</idno><imprint><date when="2014" type="published">2014</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Aged</term><term>Biomarkers (analysis)</term><term>Cohort Studies</term><term>Humans</term><term>Laser Therapy (adverse effects)</term><term>Laser Therapy (methods)</term><term>Lasers, Solid-State (therapeutic use)</term><term>Male</term><term>Middle Aged</term><term>Postoperative Complications</term><term>Prostate-Specific Antigen (analysis)</term><term>Prostatic Hyperplasia (physiopathology)</term><term>Prostatic Hyperplasia (surgery)</term><term>Quality of Life</term><term>Safety</term><term>Thulium (therapeutic use)</term><term>Transurethral Resection of Prostate (adverse effects)</term><term>Transurethral Resection of Prostate (methods)</term><term>Urinary Tract Infections (etiology)</term><term>Urination (physiology)</term><term>Volatilization</term></keywords><keywords scheme="MESH" type="chemical" qualifier="analysis" xml:lang="en"><term>Biomarkers</term><term>Prostate-Specific Antigen</term></keywords><keywords scheme="MESH" qualifier="adverse effects" xml:lang="en"><term>Laser Therapy</term><term>Transurethral Resection of Prostate</term></keywords><keywords scheme="MESH" qualifier="etiology" xml:lang="en"><term>Urinary Tract Infections</term></keywords><keywords scheme="MESH" qualifier="methods" xml:lang="en"><term>Laser Therapy</term><term>Transurethral Resection of Prostate</term></keywords><keywords scheme="MESH" qualifier="physiology" xml:lang="en"><term>Urination</term></keywords><keywords scheme="MESH" qualifier="physiopathology" xml:lang="en"><term>Prostatic Hyperplasia</term></keywords><keywords scheme="MESH" qualifier="surgery" xml:lang="en"><term>Prostatic Hyperplasia</term></keywords><keywords scheme="MESH" qualifier="therapeutic use" xml:lang="en"><term>Lasers, Solid-State</term><term>Thulium</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Aged</term><term>Cohort Studies</term><term>Humans</term><term>Male</term><term>Middle Aged</term><term>Postoperative Complications</term><term>Quality of Life</term><term>Safety</term><term>Volatilization</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">The thulium laser was introduced in 2005 for the treatment of benign prostatic hyperplasia (BPH). Enucleation studies from outside North America show comparable efficacy and lower morbidity to transurethral resection of the prostate. A few studies exist describing outcomes of vaporization, the most commonly used technique for urologists. We present our 3-month outcomes of thulium laser vaporization of the prostate (ThuVP).</div></front></TEI><pubmed><MedlineCitation Owner="NLM" Status="MEDLINE"><PMID Version="1">24936718</PMID><DateCreated><Year>2014</Year><Month>11</Month><Day>04</Day></DateCreated><DateCompleted><Year>2015</Year><Month>05</Month><Day>18</Day></DateCompleted><DateRevised><Year>2015</Year><Month>11</Month><Day>19</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1557-900X</ISSN><JournalIssue CitedMedium="Internet"><Volume>28</Volume><Issue>11</Issue><PubDate><Year>2014</Year><Month>Nov</Month></PubDate></JournalIssue><Title>Journal of endourology / Endourological Society</Title><ISOAbbreviation>J. Endourol.</ISOAbbreviation></Journal><ArticleTitle>High-power thulium laser vaporization of the prostate: short-term outcomes of safety and effectiveness.</ArticleTitle><Pagination><MedlinePgn>1357-62</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1089/end.2014.0336</ELocationID><Abstract><AbstractText Label="INTRODUCTION" NlmCategory="BACKGROUND">The thulium laser was introduced in 2005 for the treatment of benign prostatic hyperplasia (BPH). Enucleation studies from outside North America show comparable efficacy and lower morbidity to transurethral resection of the prostate. A few studies exist describing outcomes of vaporization, the most commonly used technique for urologists. We present our 3-month outcomes of thulium laser vaporization of the prostate (ThuVP).</AbstractText><AbstractText Label="MATERIALS AND METHODS" NlmCategory="METHODS">From December 2010 to October 2013, 68 men underwent ThuVP using the 150 W CyberTM(®). Data were collected on demographics, comorbidities, intraoperative measures, complications, serum parameters, maximum flow rate (Qmax), postvoid residual (PVR), International Prostate Symptom Score (IPSS), quality-of-life (QoL) score, and prostate-specific antigen. Patients were evaluated at 1 week, 1 month, and 3 months postoperatively. Nine patients were excluded for known prostate cancer.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">The mean age was 66±10 years, with a mean prostate size of 57±30 mL. At baseline, the mean IPSS was 19.9±8.0, QoL score was 4.5±1.1, Qmax was 5.2±4.5 mL/sec, and PVR was 220±397 mL. The mean laser time was 35±18 minutes, and energy used was 234±139 kJ. Forty-seven (78%) patients were discharged the day of surgery. No blood transfusions were administered with a mean drop in hemoglobin of 0.7±0.8 g/dL (p<0.05). There were no Clavien grade≥III complications within 30 days of surgery. Six (10%) patients were diagnosed with urinary tract infection. Significant improvements from baseline were seen in Qmax, PVR, IPSS, and QoL score. All 15 patients who were in retention were voiding at the last follow-up.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Thulium laser vaporization of the prostate appears to be a safe and effective outpatient technique for the treatment of BPH with durable outcomes at 3 months.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Pariser</LastName><ForeName>Joseph J</ForeName><Initials>JJ</Initials><AffiliationInfo><Affiliation>1 Section of Urology, University of Chicago , Chicago, Illinois.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Famakinwa</LastName><ForeName>Olufenwa J</ForeName><Initials>OJ</Initials></Author><Author ValidYN="Y"><LastName>Pearce</LastName><ForeName>Shane M</ForeName><Initials>SM</Initials></Author><Author ValidYN="Y"><LastName>Chung</LastName><ForeName>Doreen E</ForeName><Initials>DE</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2014</Year><Month>08</Month><Day>06</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Endourol</MedlineTA><NlmUniqueID>8807503</NlmUniqueID><ISSNLinking>0892-7790</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015415">Biomarkers</NameOfSubstance></Chemical><Chemical><RegistryNumber>8RKC5ATI4P</RegistryNumber><NameOfSubstance UI="D013932">Thulium</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.21.77</RegistryNumber><NameOfSubstance UI="D017430">Prostate-Specific Antigen</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000368">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D015415">Biomarkers</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000032">analysis</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D015331">Cohort Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D053685">Laser Therapy</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000009">adverse effects</QualifierName><QualifierName MajorTopicYN="Y" UI="Q000379">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D053844">Lasers, Solid-State</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000627">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D008875">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D011183">Postoperative Complications</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D017430">Prostate-Specific Antigen</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000032">analysis</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D011470">Prostatic Hyperplasia</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000503">physiopathology</QualifierName><QualifierName MajorTopicYN="Y" UI="Q000601">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D011788">Quality of Life</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D012449">Safety</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D013932">Thulium</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000627">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D020728">Transurethral Resection of Prostate</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000009">adverse effects</QualifierName><QualifierName MajorTopicYN="Y" UI="Q000379">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D014552">Urinary Tract Infections</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000209">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D014554">Urination</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000502">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D014835">Volatilization</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="aheadofprint"><Year>2014</Year><Month>8</Month><Day>6</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2014</Year><Month>6</Month><Day>18</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2014</Year><Month>6</Month><Day>18</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2015</Year><Month>5</Month><Day>20</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="doi">10.1089/end.2014.0336</ArticleId><ArticleId IdType="pubmed">24936718</ArticleId></ArticleIdList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Terre/explor/ThuliumV1/Data/PubMed/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000165 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd -nk 000165 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Terre
|area= ThuliumV1
|flux= PubMed
|étape= Corpus
|type= RBID
|clé= pubmed:24936718
|texte= High-power thulium laser vaporization of the prostate: short-term outcomes of safety and effectiveness.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/RBID.i -Sk "pubmed:24936718" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd \
| NlmPubMed2Wicri -a ThuliumV1
| This area was generated with Dilib version V0.6.21. |  |